Maltin Wealth Management’s ImmunityBio IBRX Stock Holding History

Maltin Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$124K	Hold	13,150	–	–	0.04%	150
2026 Q2	$115K	Hold	13,150	–	–	0.04%	144
2026 Q1	$101K	Hold	13,150	–	–	0.04%	135
2025 Q4	$26K	Hold	13,150	–	–	0.01%	132
2025 Q3	$32.3K	Buy	+13,150	New	+$33.9K	0.01%	131

Other funds holding IBRX

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return

MWM

MFG Wealth Management Indianapolis, Indiana $138M AUM 31.54% 1-Year Est. Return

CFO

Collective Family Office York, Pennsylvania $484M AUM 13.93% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return

Courier Capital Buffalo, New York $532M AUM 15.78% 1-Year Est. Return

MIC

Meridian Investment Counsel Lafayette, California $431M AUM 32.55% 1-Year Est. Return

CCIA

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

GWSA

Global Wealth Strategies & Associates Denver, Colorado $546M AUM 14.96% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Maltin Wealth Management's IBRX Position: Q3 2026 in Review

Maltin Wealth Management held its ImmunityBio (IBRX) position steady in Q3 2026 at 13,150 shares worth $124K. The position accounts for 0.04% of the portfolio, ranked #150.

Maltin Wealth Management first reported a position in IBRX in Q3 2025 and has held it in 5 quarters since. 33 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

Maltin Wealth Management held 13,150 shares of ImmunityBio worth $124K as of Q3 2026.
Maltin Wealth Management left its ImmunityBio share count unchanged in Q3 2026.
ImmunityBio made up 0.04% of Maltin Wealth Management's portfolio in Q3 2026, its #150 holding.
Maltin Wealth Management first reported a position in ImmunityBio in Q3 2025 and has held it in 5 quarters since.
33 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Maltin Wealth Management's 13F filing for Q3 2026, filed 13 Oct 2026.